Literature DB >> 8355481

Pharmacokinetics of minocycline and vancomycin in rabbits.

D P Nicolau1, C D Freeman, C H Nightingale, R Quintiliani.   

Abstract

The pharmacokinetic disposition of minocycline and vancomycin was studied in New Zealand White rabbits before initiating an experimental staphylococcal endocarditis protocol. Minocycline was administered in a multiple-dose regimen of 3 mg/kg i.v. every 12 h, 3 mg/kg i.v. every 8 h, and 6 mg/kg i.v. every 8 h. Vancomycin was given in a similar fashion using regimens of 75 mg/kg i.v. every 12 h and 50 mg/kg i.v. every 8 h. Multiple serum samples were obtained after the fifth dose and drug concentrations were analyzed by microbiologic assay. The pharmacokinetic parameters for each of the drug regimens were calculated using a two-compartment model by nonlinear least-squares regression. No statistically significant differences were noted in the volume of distribution or the half-life of the individual dosing regimens for either agent. As a result of this study, it appears that a minocycline regimen of 6 mg/kg i.v. every 8 h and a vancomycin regimen of 50 mg/kg i.v. every 8 h are appropriate dosing schemes for a comparative study of these agents in rabbits.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8355481

Source DB:  PubMed          Journal:  Lab Anim Sci        ISSN: 0023-6764


  4 in total

1.  Efficacy of vancomycin and teicoplanin alone and in combination with streptomycin in experimental, low-level vancomycin-resistant, VanB-type Enterococcus faecalis endocarditis.

Authors:  D P Nicolau; M N Marangos; C H Nightingale; K B Patel; B W Cooper; R Quintiliani; P Courvalin; R Quintiliani
Journal:  Antimicrob Agents Chemother       Date:  1996-01       Impact factor: 5.191

2.  In vivo activities of ceftriaxone and vancomycin against Borrelia spp. in the mouse brain and other sites.

Authors:  R J Kazragis; L L Dever; J H Jorgensen; A G Barbour
Journal:  Antimicrob Agents Chemother       Date:  1996-11       Impact factor: 5.191

3.  Minocycline versus vancomycin for treatment of experimental endocarditis caused by oxacillin-resistant Staphylococcus aureus.

Authors:  D P Nicolau; C D Freeman; C H Nightingale; C J Coe; R Quintiliani
Journal:  Antimicrob Agents Chemother       Date:  1994-07       Impact factor: 5.191

4.  Pharmacodynamics of vancomycin for CoNS infection: experimental basis for optimal use of vancomycin in neonates.

Authors:  V Ramos-Martín; A Johnson; J Livermore; L McEntee; J Goodwin; S Whalley; F Docobo-Pérez; T W Felton; W Zhao; E Jacqz-Aigrain; M Sharland; M A Turner; W W Hope
Journal:  J Antimicrob Chemother       Date:  2016-01-10       Impact factor: 5.790

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.